Dr. Stephen Klein

speaker

550 appearances 1 recordings 1 series first heard Jun 2026 last heard 25 Jun

Dr. Stephen Klein’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 1 in all, peaking in Jun 2026 with 1.

newest first · ▶ plays the moment

methadone.

It's more accessible to some patients than buprenorphine, but it's not something that we use at Karen Treatment Centers.

The first is potentially the easiest to understand.

The first is something called naltrexone.

Naltrexone is the same molecule, same kind of medication that's in naloxone.

Naloxone is what we give people when they're having an opioid overdose that you spray in someone's nose.

It blocks all the opioid receptors and can reverse opioid overdose.

Now, trexone is an oral version of that, so it's a pill that you take once a day.

It keeps the opioid receptors blocked.

So in essence, opioids stop working.

So it's not just a kind of protective mechanism, but what the data also shows is it decreases use and return to use.

So you start that blockade and then patients use overdose.

Basically, the markers that we talked about earlier, those outcomes all increase.

One of the issues with that medication is you have to be completely detoxed from the

Because all of a sudden they've gone from being in the extremities of euphoria and high to immediate withdrawal.

That's kind of everywhere in the body.

It can be pretty terrible.

Patients describe it as feeling really, truly awful.

So we have to make sure that whole detox period happens.

That's actually one of the biggest barriers to using naltrexone.

Showing 121–140 of 550 · page 7 of 28